Bismuth tripotassium dicitrat: from pharmaceutical characteristics to clinical efficacy

Abstract

There are pharmacodynamics, pharmacokinetics, clinical aspects of the use of bismuth tripotassium dicitrate and comparative analysis of the physicochemical and structural properties of tableted forms of preparations containing bismuth tripotassium dicitrate - the original drug De-Nol® (Astellas) and the generic drug Ulcavis® (KRKA) in the article. Demonstrated similar physical and chemical properties, the similarity of the disintegration rate of the two tablets of bismuth tripotassium dicitrate suggests a similar clinical effectiveness of the reproduced and reference drug.